20.500.12556/DiRROS-15586 Treatment outcomes and relative dose intensity of chemotherapy in patients with advanced Hodgkin lymphoma The present retrospective study was undertaken to investigate the association of relative dose intensity (RDI) with the outcome of patients with advanced stage Hodgkin lymphoma (HL) receiving ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and escalated BEACOPP regimens (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone). A total of 114 patients with HL treated between 2004 and 2013 were enrolled for evaluation. The association of variables with overall survival (OS) and progression-free survival (PFS) was analysed using univariate and multivariate Cox proportional hazards models. The median age of patients was 39 years, and the majority were male and had stage IV disease. A total of 54 patients received ABVD and 60 received BEACOPP chemotherapy with 24 and four deaths, respectively. Patients in the BEACOPP group were significantly younger with lower Charlson comorbidity index (CCI) and better performance status in comparison with the ABVD group, making the comparison of groups not possible. In the ABVD group, RDI was not significantly associated with OS (P=0.590) or PFS (P=0.354) in a multivariate model where age was controlled. The low number of events prevented this analysis in the BEACOPP group. The age of patients was strongly associated with both OS and PFS; all statistically significant predictors for OS and PFS from univariate analyses (chemotherapy regimen, CCI, RDI, performance status) lost their effect in multivariate analyses where age was controlled. Based on these observations, it was concluded that RDI was not associated with OS or PFS after age is controlled, neither in all patients combined nor in the ABVD group. Hodgkin lymphoma chemotherapy outcome primary treatment Hodgkinov limfom kemoterapija neželeni učinki osnovno zdravljenje true false true Spandidos Angleški jezik Slovenski jezik by Authors Neznano 2022-09-23 03:34:34 2022-09-23 14:32:06 2022-09-24 03:44:04 0000-00-00 00:00:00 2022 0 0 str. 320-1-320-7 no. 3 Vol. 24 2022 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 2022-07-19 616.1/.4 1792-1074 10.3892/ol.2022.13440 118357251 RAZ_Rozman_Samo_2022.pdf RAZ_Rozman_Samo_2022.pdf 1 A18205F1484753CF9F49F5874A13DECA 7e0bd06c163e17839183ea86f592e924eed3bbad96bd8b93ebd5633cdfb6dcb5 61105895-3b2b-11ed-bea5-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=20624 Onkološki inštitut Ljubljana 0 0 0